Free Newsletter
FDA nixes melanoma use for PegIntron
Free newsletter via e-mail
Tools
Despite an advisory panel's recommendation, the FDA has declined to approve a new use for Schering-Plough's PegIntron, saying that it has "outstanding concerns" about a melanoma indication for the drug. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: